HER2+ 유방암

208개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved208 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Relatlimab FDC + Nivolumab)

Metastatic Triple-negative Breast Cancer · Metastatic Triple-negative Breast Cancer

#MetastaticTriple-negativeBreastC#Antibody#Phase2#monoclonal-antibody#Bristol
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePreclinical

proposed trastuzumab biosimilar (SB3, SB3 (proposed trastuzumab biosimilar))

Breast Neoplasms · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#BreastNeoplasms+1
Trials 1Status Discontinued
ADCLimited DatastaleGileadPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan)

Metastatic Breast Cancer ( HER2 Negative) · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MetastaticBreastCancerHER2Negati+1
Trials 1Status Recruiting
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
AntibodyLimited DatastaleElevation OncologyPhase 2

Seribantumab (Seribantumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#Elevation
Trials 1Status Discontinued
AntibodyLimited DatastaleAgendiaApproved

trastuzumab (Herceptin, T + trastuzumab followed by CEF + trastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Approved#monoclonal-antibody#Agendia
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

T cells modified with RNA anti -cMET CAR (T cells modified with RNA anti -cMET CAR)

Malignant Melanoma; Breast Cancer · Malignant Melanoma

#MalignantMelanoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleTriumvira Immunologics, Inc.Phase 2

pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)

HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2PositiveGastricCancer+2
Trials 1Status Discontinued
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

Breast Cancer · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleTJ Biopharma Co., Ltd.Phase 2

pembrolizumab (Keytruda, TJ107 +Pembrolizumab)

Triple-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#Antibody#Phase2#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleNanlin LiPreclinical

trastuzumab (Herceptin, TP Chemotherapy + Trastuzumab + Pertuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

trastuzumab (TX05, TX05 (trastuzumab))

Breast Cancer; Breast Neoplasms · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

trastuzumab (Herceptin, Taxanes combined with trastuzumab and pertuzumab.)

Advanced HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedHER2-positiveBreastCance+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （12weeks） (Toripalimab （12weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab （18weeks） (Toripalimab （18weeks）)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleNorthwestern UniversityPhase 1

Transferrin Receptor-Targeted Liposomal p53 cDNA (Transferrin Receptor-Targeted Liposomal p53 cDNA)

Anatomic Stage IV Breast Cancer AJCC v8; Breast Inflammatory Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase1#monoclonal-antibody#BreastInflammatoryCarcinoma+1
Trials 1Status Discontinued
ADCLimited DatastaleDaiichi SankyoPreclinical

T-DXd, ENHERTU® (Trastuzumab Deruxtecan, Trastuzumab Deruxtecan (T-DXd, ENHERTU®))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

SHR-A1811 (Trastuzumab Rezetecan, Trastuzumab Rezetecan (SHR-A1811))

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveBreastCancer+1
Trials 1Status Recruiting

9 / 11 pages

← PreviousNext →